Type II monocytes modulate T cell-mediated central nervous system autoimmune disease

Martin S. Weber, Thomas Prod'homme, Sawsan Youssef, Shannon E. Dunn, Cynthia D. Rundle, Linda Lee, Juan C. Patarroyo, Olaf Stüve, Raymond A. Sobel, Lawrence Steinman, Scott S. Zamvil

Research output: Contribution to journalArticle

342 Citations (Scopus)

Abstract

Treatment with glatiramer acetate (GA, copolymer-1, Copaxone), a drug approved for multiple sclerosis (MS), in a mouse model promoted development of anti-inflammatory type II monocytes, characterized by increased secretion of interleukin (IL)-10 and transforming growth factor (TGF)-β, and decreased production of IL-12 and tumor necrosis factor (TNF). This anti-inflammatory cytokine shift was associated with reduced STAT-1 signaling. Type II monocytes directed differentiation of TH2 cells and CD4+CD25 +FoxP3+ regulatory T cells (Treg) independent of antigen specificity. Type II monocyte-induced regulatory T cells specific for a foreign antigen ameliorated experimental autoimmune encephalomyelitis (EAE), indicating that neither GA specificity nor recognition of self-antigen was required for their therapeutic effect. Adoptive transfer of type II monocytes reversed EAE, suppressed TH17 cell development and promoted both TH2 differentiation and expansion of Treg cells in recipient mice. This demonstration of adoptive immunotherapy by type II monocytes identifies a central role for these cells in T cell immune modulation of autoimmunity.

Original languageEnglish (US)
Pages (from-to)935-943
Number of pages9
JournalNature Medicine
Volume13
Issue number8
DOIs
StatePublished - Aug 2007

Fingerprint

Autoimmune Diseases of the Nervous System
T-cells
Central Nervous System Diseases
Neurology
Monocytes
T-Lymphocytes
Regulatory T-Lymphocytes
Anti-Inflammatory Agents
Autoimmune Experimental Encephalomyelitis
Antigens
Autoantigens
Transforming Growth Factors
Interleukin-12
Interleukin-10
Demonstrations
Adoptive Immunotherapy
Th17 Cells
Copolymers
Tumor Necrosis Factor-alpha
Modulation

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Weber, M. S., Prod'homme, T., Youssef, S., Dunn, S. E., Rundle, C. D., Lee, L., ... Zamvil, S. S. (2007). Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nature Medicine, 13(8), 935-943. https://doi.org/10.1038/nm1620

Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. / Weber, Martin S.; Prod'homme, Thomas; Youssef, Sawsan; Dunn, Shannon E.; Rundle, Cynthia D.; Lee, Linda; Patarroyo, Juan C.; Stüve, Olaf; Sobel, Raymond A.; Steinman, Lawrence; Zamvil, Scott S.

In: Nature Medicine, Vol. 13, No. 8, 08.2007, p. 935-943.

Research output: Contribution to journalArticle

Weber, MS, Prod'homme, T, Youssef, S, Dunn, SE, Rundle, CD, Lee, L, Patarroyo, JC, Stüve, O, Sobel, RA, Steinman, L & Zamvil, SS 2007, 'Type II monocytes modulate T cell-mediated central nervous system autoimmune disease', Nature Medicine, vol. 13, no. 8, pp. 935-943. https://doi.org/10.1038/nm1620
Weber MS, Prod'homme T, Youssef S, Dunn SE, Rundle CD, Lee L et al. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nature Medicine. 2007 Aug;13(8):935-943. https://doi.org/10.1038/nm1620
Weber, Martin S. ; Prod'homme, Thomas ; Youssef, Sawsan ; Dunn, Shannon E. ; Rundle, Cynthia D. ; Lee, Linda ; Patarroyo, Juan C. ; Stüve, Olaf ; Sobel, Raymond A. ; Steinman, Lawrence ; Zamvil, Scott S. / Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. In: Nature Medicine. 2007 ; Vol. 13, No. 8. pp. 935-943.
@article{3d39e2531e0a4f339d06634fe52ef367,
title = "Type II monocytes modulate T cell-mediated central nervous system autoimmune disease",
abstract = "Treatment with glatiramer acetate (GA, copolymer-1, Copaxone), a drug approved for multiple sclerosis (MS), in a mouse model promoted development of anti-inflammatory type II monocytes, characterized by increased secretion of interleukin (IL)-10 and transforming growth factor (TGF)-β, and decreased production of IL-12 and tumor necrosis factor (TNF). This anti-inflammatory cytokine shift was associated with reduced STAT-1 signaling. Type II monocytes directed differentiation of TH2 cells and CD4+CD25 +FoxP3+ regulatory T cells (Treg) independent of antigen specificity. Type II monocyte-induced regulatory T cells specific for a foreign antigen ameliorated experimental autoimmune encephalomyelitis (EAE), indicating that neither GA specificity nor recognition of self-antigen was required for their therapeutic effect. Adoptive transfer of type II monocytes reversed EAE, suppressed TH17 cell development and promoted both TH2 differentiation and expansion of Treg cells in recipient mice. This demonstration of adoptive immunotherapy by type II monocytes identifies a central role for these cells in T cell immune modulation of autoimmunity.",
author = "Weber, {Martin S.} and Thomas Prod'homme and Sawsan Youssef and Dunn, {Shannon E.} and Rundle, {Cynthia D.} and Linda Lee and Patarroyo, {Juan C.} and Olaf St{\"u}ve and Sobel, {Raymond A.} and Lawrence Steinman and Zamvil, {Scott S.}",
year = "2007",
month = "8",
doi = "10.1038/nm1620",
language = "English (US)",
volume = "13",
pages = "935--943",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Type II monocytes modulate T cell-mediated central nervous system autoimmune disease

AU - Weber, Martin S.

AU - Prod'homme, Thomas

AU - Youssef, Sawsan

AU - Dunn, Shannon E.

AU - Rundle, Cynthia D.

AU - Lee, Linda

AU - Patarroyo, Juan C.

AU - Stüve, Olaf

AU - Sobel, Raymond A.

AU - Steinman, Lawrence

AU - Zamvil, Scott S.

PY - 2007/8

Y1 - 2007/8

N2 - Treatment with glatiramer acetate (GA, copolymer-1, Copaxone), a drug approved for multiple sclerosis (MS), in a mouse model promoted development of anti-inflammatory type II monocytes, characterized by increased secretion of interleukin (IL)-10 and transforming growth factor (TGF)-β, and decreased production of IL-12 and tumor necrosis factor (TNF). This anti-inflammatory cytokine shift was associated with reduced STAT-1 signaling. Type II monocytes directed differentiation of TH2 cells and CD4+CD25 +FoxP3+ regulatory T cells (Treg) independent of antigen specificity. Type II monocyte-induced regulatory T cells specific for a foreign antigen ameliorated experimental autoimmune encephalomyelitis (EAE), indicating that neither GA specificity nor recognition of self-antigen was required for their therapeutic effect. Adoptive transfer of type II monocytes reversed EAE, suppressed TH17 cell development and promoted both TH2 differentiation and expansion of Treg cells in recipient mice. This demonstration of adoptive immunotherapy by type II monocytes identifies a central role for these cells in T cell immune modulation of autoimmunity.

AB - Treatment with glatiramer acetate (GA, copolymer-1, Copaxone), a drug approved for multiple sclerosis (MS), in a mouse model promoted development of anti-inflammatory type II monocytes, characterized by increased secretion of interleukin (IL)-10 and transforming growth factor (TGF)-β, and decreased production of IL-12 and tumor necrosis factor (TNF). This anti-inflammatory cytokine shift was associated with reduced STAT-1 signaling. Type II monocytes directed differentiation of TH2 cells and CD4+CD25 +FoxP3+ regulatory T cells (Treg) independent of antigen specificity. Type II monocyte-induced regulatory T cells specific for a foreign antigen ameliorated experimental autoimmune encephalomyelitis (EAE), indicating that neither GA specificity nor recognition of self-antigen was required for their therapeutic effect. Adoptive transfer of type II monocytes reversed EAE, suppressed TH17 cell development and promoted both TH2 differentiation and expansion of Treg cells in recipient mice. This demonstration of adoptive immunotherapy by type II monocytes identifies a central role for these cells in T cell immune modulation of autoimmunity.

UR - http://www.scopus.com/inward/record.url?scp=34547699396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547699396&partnerID=8YFLogxK

U2 - 10.1038/nm1620

DO - 10.1038/nm1620

M3 - Article

C2 - 17676050

AN - SCOPUS:34547699396

VL - 13

SP - 935

EP - 943

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 8

ER -